Fig. 3: TMB values across different assays and tumor fraction dynamics according to clinical benefit. | Nature Communications

Fig. 3: TMB values across different assays and tumor fraction dynamics according to clinical benefit.

From: Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

Fig. 3

A Distribution of the 12 paired tissue and baseline blood samples showing the tissue, blood, and OncoPanel TMB or bTMB, respectively. B Correlation between the tissue TMB and baseline bTMB showing the significant positive correlation with bTMB. C The correlation between baseline bTMB and OncoPanel TMB reveals a significantly higher bTMB. D The correlation between tissue and OncoPanel TMB shows a significant positive correlation between them, and the strongest correlation among the different TMB panels. P-values in (B–D) are two-sided Student t tests for the Pearson correlation coefficient r. E Changes in tumor fraction from seven paired baseline and end of treatment patients reveal a significant correlation based on clinical benefit status. P-value is an unpaired two-sided Wilcoxon rank-sum test between the clinical benefit groups using paired tumor fraction changes per patient. Patients 1 and 7 had similar changes in tumor fraction, and they overlap in the trajectory plot.

Back to article page